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We screened small molecules to identify two com-
pounds, which we named RSL3 and RSL5, that
have increased lethality in the presence of oncogenic
RAS. Counter screeningwith biologically active com-
pounds defined aspects of the mechanism of action
forRSL3andRSL5, such as anonapoptotic,MEK-de-
pendent, and iron-dependent oxidative cell death.
Erastin, a previously reported compound with RAS-
selective lethality, showed similar properties. RNA in-
terference experiments targeting voltage-dependent
anion channel 3 (VDAC3), a target of erastin, demon-
strated that RSL5 is a scaffold that acts through
VDACs to activate the observed pathway. RSL3 acti-
vated a similar deathmechanism but in a VDAC-inde-
pendent manner. We found that cells transformed
with oncogenic RAS have increased iron content
relative to their normal cell counterparts through up-
regulation of transferrin receptor 1 and downregula-
tion of ferritin heavy chain 1 and ferritin light chain.
INTRODUCTION
Leads for new cancer therapeutics often emerge from target-
based, in vitro screening. Targeted kinase inhibitors, such as
Gleevec and Iressa have been effective in treating tumors by us-
ing a targeted therapy approach. However, many proteins cannot
be targeted with enzymatic, active-site inhibitors. RAS, the most
frequently mutated oncogene, is mutated in a way that causes
loss of its GTPase activity, thereby activating downstream effec-
tors of RAS pathways. Restoring GTPase function to mutant RAS
with pharmacological agents is a challenging task compared to
the traditional approach of discovering enzyme inhibitors.
To circumvent this problem, efforts have been made to target
related signaling pathways instead of the mutant protein per se.
For example, oncogenic RAS cannot hydrolyze bound GTP and
consequently binds downstream signaling proteins, including
RAF, PI3K, RalGDS, and PLC3 in its GTP-bound form. As activa-
tion of multiple downstream signaling molecules are crucial to
RAS-mediated tumorigenesis and tumor maintenance, discov-
ery of inhibitors targeting these downstream molecules may
lead to novel anticancer drugs: Sorafenib (Wilhelm et al., 2006),234 Chemistry & Biology 15, 234–245, March 2008 ª2008 Elsevier La RAF kinase inhibitor, was approved by the FDA in the U.S.
for the treatment of renal cell carcinoma.
Nonetheless, to date, efforts to target RAS signaling have
been focused mostly on target-based, in vitro screening. RAS
is proposed to interact with more than 360 proteins (Bernards,
2005), and it is possible that distal downstream components of
the oncogenic-RAS-signaling network could be targets for
drug discovery. A strategy for revealing these critical RAS-linked
targets is synthetic lethal screening (Hartwell et al., 1997). For
a given mutation ‘‘A,’’ if there exists a second mutation ‘‘B’’
that is particularly lethal to the organism in the presence of A,
mutation B is synthetic lethal with mutation A because the lethal-
ity requires the synthesis, or bringing together, of the two muta-
tions. In synthetic lethal screening with oncogenic RAS, the sec-
ond perturbation can be created by using a small molecule to
alter the function of a target protein rather than by introducing
a mutation in the gene encoding the protein (Figure 1A; Stock-
well, 2000).
The existence of striking synthetic lethal interactions in ge-
nome-wide studies has been demonstrated with yeast deletion
strains (Tong et al., 2001). Each yeast gene has on average 30
synthetic lethal/sick interactions with other yeast genes. In anti-
cancer therapeutics, several compounds have been reported to
display synthetic lethality, including (1) RB with topoisomerase II
inhibitors (Banerjee et al., 1998), (2) PTEN with mTOR inhibitors
(Neshat et al., 2001), and (3) BRCA1 with PARP inhibitors (Bryant
et al., 2005). In accord with the concept of synthetic lethality,
cancer cells with mutations in RB, PTEN, or BRCA1 are more
sensitive to the respective compound treatments than normal
cells without such mutations.
We have pursued synthetic lethal screening with small mole-
cules to identify those that display synthetic lethality with onco-
genic RAS; we reported that the compound erastin has this prop-
erty (Dolma et al., 2003). As expected, the target of erastin is not
RAS itself: erastin binds to voltage-dependent anion channels,
a novel target for anticancer drugs, to induce RAS-RAF-MEK-de-
pendent oxidative, nonapoptotic cell death (Yagoda et al., 2007).
We used a series of engineered cell lines derived from primary
human fibroblasts for screening (Figure 1B; Dolma et al., 2003;
Hahn et al., 1999). Briefly, BJ cells were engineered successively
to express the catalytic subunit of human telomerase (hTERT),
the SV40 large T and small T antigens (LT and ST), and an onco-
genic allele of HRAS (HRASG12V). We named these cells lines
BJ-TERT, BJ-TERT/LT/ST, and BJ-TERT/LT/ST/RASV12. Only
the BJ-TERT/LT/ST/RASV12 cells form tumors in nude mice.td All rights reserved
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BJ-TERT/LT/ST/RASV12 cells while having minimal effects on
their isogenic cell precursors. It should be noted that while we
used oncogenic HRAS in the primary screen, we tested all hit
compounds for their selectivity against oncogenic KRAS, which
is more commonly mutated in human cancers.
Here, we report the results of screening using a refined cell line
system, a novel collection of small molecules, and a systematic
analysis of mechanism of action. We identified two novel small
molecules that have synthetic lethal interactions with mutant
RAS and characterized their mechanism of action, which lead
to the discovery that oncogenic RAS signaling enriches the
cellular iron pool by modulating the iron metabolism network.
RESULTS
Identification of Small Molecules that Are Synthetic
Lethal to Oncogenic RAS
We developed a new screening cascade for discovering genet-
ically selective compounds and ruling out proliferation-depen-
dent compounds (Figure 1C). We collected 47,725 compounds
Figure 1. Overview of Our Synthetic Lethal
Screening Strategy
(A) Two genes (in this case, RAS and Protein X,
a target of a small molecule) are synthetic lethal
if perturbations in either alone has little conse-
quence to the cell, but simultaneous perturbation
of both causes death. Perturbation of protein X
can be produced by either genetic mutation or
small-molecule treatment.
(B) Characteristics of isogenic cell lines used for
synthetic lethal screening. Sequential introduction
of oncogenic elements converts human primary
fibroblast cells into tumorigenic cells. Phenotypic
changes associated with expression of each
genetic element are indicated along with cell
doubling time. Both RASV12 harboring cells
(BJ-TERT/LT/ST/RASV12 and BJ-TERT/p53DD/
CDK4/cyclinD1/ST/RASV12 cells) can form tumors
in nude mice but differ in cell doubling time, which
allows filtering out proliferation-rate-dependent
lethal compounds.
(C) Flow chart of our screening strategy.
(D) Structure of RSL5 and RSL3.
that are either synthetic or natural-prod-
uct derivatives. All compounds were
tested in BJ-TERT/LT/ST/RASV12 cells
in 384-well plates (one compound per
well) at a concentration of 5 mg/ml, corre-
sponding to 13 mM for a compound with
a molecular weight of 400. After 2 days
of incubation, cell viability was assessed
with alamar blue, which detects changes
in cellular reductive potential (Nociari
et al., 1998).
Compounds that inhibited alamar blue
metabolism in BJ-TERT/LT/ST/RASV12
cells more than 50% were considered ini-
tial hits and tested in an extensive 2-fold
dilution series in BJ-TERT/LT/ST/RASV12 cells and in isogenic
cells lacking oncogenic RAS (BJ-TERT and BJ-TERT/LT/ST)
and in a nearly isogenic, tumorigenic cell line that grows slowly
(BJ-TERT/p53DD/CDK4/cyclinD1/ST/RASV12 cells, hereafter,
DRD cells, see below).
We refined this screening system by incorporating DRD cells,
which were engineered to express hTERT, SV40 small T onco-
protein, oncogenic HRAS (HRASG12V), dominant negative p53,
and constitutively active CDK4/cyclinD, which inactivates the
RB protein. The p53DD/CDK4/cyclinD1 combinations substitute
for the SV40 large T oncoprotein (Figure 1B; Dolma et al., 2003;
Hahn et al., 2002). Given that DRD cells are also derived from
BJ primary cells and the effects of mutations in both lines
should be similar, ideal synthetic lethal compounds should
have similar growth inhibitory potency in DRD cells and BJ-TERT/
LT/ST/RASV12 cells. Both BJ-TERT/LT/ST/RASV12 cells and DRD
cells form tumors in nude mice, but the doubling time of DRD cells
is significantly longer than that of BJ-TERT/LT/ST/RASV12 cells
in vitro (Figure 1B). Thus, the use of DRD cells as a counter
screen enabled us to eliminate compounds that (1) have idio-
syncratic activity in BJ-TERT/LT/ST/RASV12 cells, (2) are simplyChemistry & Biology 15, 234–245, March 2008 ª2008 Elsevier Ltd All rights reserved 235
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Oncogenic-RAS-Signaling-Dependent Lethal Compoundsmore potent in rapidly dividing cells, or (3) are dependent on the
SV40 viral protein rather than an endogenous oncogenic signal-
ing pathway.
After analyzing the results of the 2-fold dilution series testing,
we picked two novel compounds, which we have named RSL3
and RSL5, for oncogenic-RAS-selective lethal compounds, as
our finalhits, because they displayed synthetic lethalitywithonco-
genic RAS in both BJ-TERT/LT/ST/RASV12 and DRD cells
(Figure 1D). We confirmed the cell killing effect of these com-
pounds by using a trypan blue assay (see below). The presence of
oncogenic RAS signaling is required for more efficient cell killing
by these compounds. The IC50 value in BJ-TERT/LT/ST/RAS
V12
cells was similar to that in DRD cells, which indicates that the syn-
Figure 2. Effect of RSL5 on Four BJ-Derived Cell Lines and Results
of Counter Screening with Bioactive Molecules
(A) BJ-TERT, BJ-TERT/LT/ST, BJ-TERT/LT/ST/RASV12, and DRD cells were
treated with RSL5 in 384-well plates for 48 hr. Error bars indicate one standard
deviation of triplicate data.
(B and C) BJ-TERT/LT/ST/RASV12 cells were treated with RSL5 in the presence
of the indicated bioactive molecules in 384-well plates for 24 hr. The concen-
tration of each bioactive compound is listed in Table S1. Percent growth inhi-
bition was measured with alamar blue. The graph is a representative outcome
of multiple experiments.236 Chemistry & Biology 15, 234–245, March 2008 ª2008 Elsevier Lthetic lethal interaction is relevant beyond a single cell line (Fig-
ures 2A and 3A) and that the compounds are not proliferation
dependent in their activity. Thus, this screening cascade yielded
two novel compounds that have a degree of synthetic lethality
with oncogenic RAS.
Mechanism of Action Study with a Set of Biologically
Active Molecules
To assess potential mechanisms of action underlying cell death
induced by RSL5 and RSL3, our strategy was to test a series of
biologically active compounds for their ability to suppress cell
death induced by RSL3 or RSL5. This is akin to a genetic sup-
pressor screen, except that we are making use of small mole-
cules in place of mutations. The compounds were chosen based
on their reported ability to inhibit aspects of cell death signaling
Figure 3. Effect of RSL3 on Four BJ-Derived Cell Lines and Results
of Counter Screening with Bioactive Molecules
(A) BJ-TERT, BJ-TERT/LT/ST, BJ-TERT/LT/ST/RASV12, and DRD cells were
treated with RSL3 in 384-well plates for 48 hr. Data represents the mean ± SD
of triplicate samples.
(B and C) BJ-TERT/LT/ST/RASV12 cells were treated with RSL3 in the presence
of indicated bioactive compounds in 384-well plates for 24 hr. The concentra-
tion of each bioactive compound was listed in Table S1. Percent growth inhi-
bition was measured with alamar blue. The graph is a representative outcome
of multiple experiments.td All rights reserved
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Oncogenic-RAS-Signaling-Dependent Lethal Compounds(z-VAD-fmk, Boc-D-fmk, vitamin E, reduced gluthathione [GSH],
desferrioxamine mesylate [DFOM], and cycloheximide [CycH])
or kinase signaling related to RAS (U0126, SB203580, Wortman-
nin, Rapamycin, and SU6656) (see Table S1 in the Supplemental
Data available with this article online for detailed information).
We treated BJ-TERT/LT/ST/RASV12 cells with an individual
bioactive compound, along with either RSL5 or RSL3, and mon-
itored changes in cell sensitivity (Figures 2B, 2C, 3B, and 3C).
RSL5 and RSL3 shared many properties. First, caspase inhibi-
tors (z-VAD-fmk, Boc-D-fmk) were not effective at suppressing
cell death induced by RSL3 or RSL5, despite the fact that these
pan-caspase inhibitors efficiently suppress cell death induced
by other apoptotic stimuli (Varma et al., 2007); therefore,
RSL5-induced and RSL3-induced cell death is caspase inde-
pendent (Figures 2B and 3B).
Second, an iron chelator (DFOM) and an antioxidant (vitamin E)
were able to inhibit RSL5-induced and RSL3-induced cell death,
suggesting involvement of Fenton chemistry and reactive oxy-
gen species (ROS) (Figures 2B and 3B).
Third, a SRC kinase inhibitor (SU6656) blocked RSL5-induced
cell death and suppressed RSL3-induced cell death (Figures 2C
and 3C). SRC kinase is known to act as an upstream regulator of
the RAS signaling pathway (Smith et al., 1986). Thus, treatment
with this SRC kinase inhibitor likely attenuates oncogenic RAS
signaling.
Finally, a MEK1/2 inhibitor (U0126) was able to suppress RSL5-
induced and RSL3-induced cell death, demonstrating that it is
specifically the RAS-RAF-MEK pathway that causes RSL5 and
RSL3 sensitivity, as opposed to other aspects of RAS signaling.
For example, a PI3K inhibitor (wortmannin), an mTOR inhibitor
(rapamycin), and a SAPK inhibitor (SB203580) were all without
effect on sensitivity to RSL5 and RSL3 (Figures 2C and 3C).
While RSL5 and RSL3 share a number of properties, we did
see some differences upon protein-synthesis inhibitor (CycH)
treatment (Figures 2B and 3B). RSL5 required protein synthesis
to induce cell death, while RSL3 did not.
Both BJ-TERT/LT/ST/RASV12 cells and DRD cells are engi-
neered cell lines. To test the effect of these compounds in gen-
uine tumor cells, we explored their lethality in HT1080 cells.
Our goal was to determine whether the oncogenic-RAS-signal
dependent lethality of RSL5 and RSL3 was relevant beyond
these engineered cell lines. HT1080 cells originate from a human
fibrosarcoma, contain an oncogenic RAS mutation (NRAS
Q61A), and are tumorigenic in nude mice. In these experiments,
we included erastin, which we previously reported as an inducer
of synthetic lethality with oncogenic RAS. We found previously
that erastin induces RAS-RAF-MEK-dependent oxidative cell
death (Yagoda et al., 2007).
Bioactive compounds that suppressed RSL5 or RSL3 (DFOM,
vitamin E, CycH, U1026, and SU6656) were tested against era-
stin, RSL5, and RSL3 in HT1080 cells (Figure S1). All three lethal
compounds were suppressed by the SRC inhibitor (SU6656) and
the MEK inhibitor (U0126), confirming the RAS-RAF-MEK-de-
pendent lethality in these HT1080 cells. Antioxidants (e.g., vita-
min E) and iron chelators (e.g., DFOM) were able to suppress
cell death induced by these three lethal compounds. Therefore,
all three compounds (erastin, RSL5, and RSL3) induce a similar
phenotype, that is, a RAS-RAF-MEK-dependent oxidative,
iron-dependent cell death. However, a protein synthesis inhibitorChemistry & Biology 1(CycH) was able to suppress cell death induced by erastin and
RSL5, but not RSL3, implying the precise mechanism of action
of RSL5 and RSL3 might be different (Figure S1).
Involvement of VDAC3 in Erastin-Induced
and RSL5-Induced Cell Death
As erastin, RSL5, and RSL3 emerged from a similar screening
setting and share a common genetic selectivity and induced
phenotype, we wanted to determine whether RSL5 and RSL3
act through the same mechanism as erastin, by engaging mito-
chondrial VDACs. By using affinity purification and mass spec-
trometry, mitochondrial voltage-dependent anion channels
(VDACs) were identified as specific targets of erastin (Yagoda
et al., 2007).
Mammalian cells have three VDAC isoforms, VDAC1, VDAC2,
and VDAC3. An erastin affinity analog specifically purified
VDAC2 and VDAC3 only in lysates of BJ-TERT/LT/ST/RASV12
cells, not of BJ-TERT cells. RNA interference experiments tar-
geting VDAC2 and VDAC3 demonstrated that erastin binding
to VDAC2 and VDAC3 induces a gain-of-function lethality:
knocking down VDAC3 makes cells resistant to erastin, and
knocking down VDAC2 reduces their sensitivity to erastin
(Yagoda et al., 2007).
To test the possibility of VDAC involvement in the synthetic
lethal action of RSL5 and RSL3, we knocked down VDAC3 in
HT1080 cells by using short hairpin RNAs (shRNAs) specifically
targeting vdac3. Knockdown of VDAC3 protein suppressed era-
stin-induced and RSL5-induced cell death, whereas RSL3 le-
thality was not affected (Figure 4). Introduction of shRNAs target-
ing VDAC3 did not change the level of other VDAC isoforms
(VDAC1 and VDAC2), as assessed by quantitative PCR (Q-
PCR) (Figure S2). Thus, RSL5 acts through at least VDAC3, as
does erastin. However, RSL3 appears to act in a VDAC-indepen-
dent manner. This is significant, because it demonstrates that
the oxidative, nonapoptotic cell death pathway targeted by
these compounds is not restricted to VDAC involvement but
can be activated under other conditions and may be more
generally important.
RSL3 Has Oncogenic-RAS-Signal Dependent Lethality
with a Unique Sensitivity Profile
RSL3’s ability to induce synthetic lethality with oncogenic RAS
was rapid and quite potent. This compound inhibited the growth
of BJ-TERT/LT/ST/RASV12 and DRD cells as low as 10 ng/ml
(Figure 3A) and started to kill sensitive cells as early as 8 hr after
treatment (Figures 5A and 5C). We carried out a trypan blue
exclusion assay to confirm the growth inhibitory effect and the
selectivity of RSL3. This was performed in a Vi-Cell (Beckman
Coulter), which stains cells with trypan blue, takes 100 images,
and analyzes the images to calculate the number of viable cells
(i.e., cells excluding trypan blue). This assay eliminates false
positives caused by autofluorescence or redox activity from
a compound in the alamar blue assay. The trypan blue exclusion
assays with RSL3 revealed a similar level of potency and selec-
tivity as the alamar blue assay (Figure 5B). Moreover, longer
treatment with RSL3 had little effect on the viability of cells lack-
ing oncogenic RAS, confirming the qualitative nature of RSL3’s
selectivity (Figure 5B).5, 234–245, March 2008 ª2008 Elsevier Ltd All rights reserved 237
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Oncogenic-RAS-Signaling-Dependent Lethal CompoundsCell death induced by RSL3 treatment was not blocked by
pan-caspase inhibitors (z-VAD-fmk, Boc-D-fmk), suggesting
that a caspase-independent death pathway is involved in
RSL3-induced cell death (Figures 2B and 3B). Because the
survival effect of caspase inhibitors can be masked by activation
Figure 4. RSL5 andErastin Utilize VDAC3 toCreate Synthetic Lethal-
ity with RAS
HT1080 cells were infected with lentivirus-encoding shRNAs targeting VDAC3
and treated with erastin (A), RSL5 (B), or RSL3 (C). Expression of shRNAs tar-
geting VDAC3 prevented cell death caused by RSL5 and erastin, whereas the
sensitivity of RSL3 was not changed. Percent growth inhibition was deter-
mined with alamar blue. Error bars indicate one standard deviation of triplicate
data.238 Chemistry & Biology 15, 234–245, March 2008 ª2008 Elsevier Lof alternative cell death pathways upon drug treatment, we em-
ployed a more sensitive measurement of caspase activation to
examine the possible involvement of caspases in RSL3-induced
cell death. Poly(ADP-ribose) polymerase-1 (PARP-1) is an abun-
dant nuclear enzyme that is subject to cleavage by activated
caspase 3/7. We compared staurosporine, erastin, RSL5, and
RSL3 treatments of BJ-TERT/LT/ST/RASV12 cells, prepared
cell lysates, and analyzed PARP-1 cleavage by western blot
with an anti-PARP-1 antibody (Figure 5D). Only staurosporine-
treated sample showed PARP-1 cleavage, indicating that staur-
osporine induces classical apoptotic cell death involving cas-
pases, whereas erastin, RSL5, and RSL3 activate a nonapoptotic
pathway (Figure 5D).
Among the threeRAS genes (HRAS, KRAS,NRAS), the BJ cell
system employed HRAS mutations to initiate oncogenic signals.
All three RAS proteins can activate common downstream effec-
tors but, for elusive reasons, human cancer cells have biased
mutation rates among the threeRAS genes; more than 70% con-
tain KRAS mutations, 25% NRAS mutations, and less than 5%
HRAS mutations (Rodenhuis, 1992). Since KRAS mutations are
the most prevalent in human cancers, we tested the activity of
RSL3 in KRAS-mutation-harboring cancer cells (Figure 6A).
This compound was active in all oncogenic-KRAS-harboring
cancer cell lines tested (Figure 6A). Among them, Calu-1 cells
were the most sensitive to RSL3 (Figure 6A); the IC50 in Calu-1
cells was 20 ng/ml.
Considering RSL3’s high potency, we reasoned it would be in-
teresting to test this compound in a broader range of cancer cell
lines and see if there exist additional cell lines, like Calu-1, that
are particularly sensitive. We submitted RSL3 to the Develop-
mental Therapeutics Program (DTP) at the NCI in order to test
this possibility. RSL3 was tested in 60 different human cancer
cell lines (the NCI60 panel), and the growth inhibitory potency
of RSL3 was determined across these cell lines. A number of
cell lines were particularly sensitive to RSL3 treatment; nanomo-
lar concentrations of RSL3 were often sufficient to induce growth
arrest or cell killing, and there was up to 104-fold differences in
sensitivity between resistant and sensitive cell lines (Figure 6B
and Figure S3). Moreover, the sensitivity profile of RSL3 across
the 60 cancer cell lines was distinct from those of known com-
pounds in the NCI database, as assessed by the COMPARE
algorithm (Paull et al., 1989), which suggests the mechanism
of action for RSL3 is unique (Figure 6B). The COMPARE algo-
rithm compares sensitivity profiles of an input compound to
those of all other compounds in the database and returns a sim-
ilarity score in terms of pairwise correlation coefficient (PCC).
In control tests, the sensitivity profile of paclitaxel grouped
with vinblastine, maytansine, and rhizoxin, with high PCC values
(Figure 6B). All of these compounds are known to perturb micro-
tubule integrity, which demonstrates the usefulness of the
COMPARE algorithm to understand the mechanism of com-
pound action. In contrast, the COMPARE analysis of RSL3
returned only compounds with low PCC values (Figure 6B). In
other words, no compounds in the NCI database had a similar
pattern of cell killing as RSL3.
We inferred that the oncogenic-RAS-signal-dependent lethal-
ity of RSL3 should persist in cancer cell lines other than HRAS-
transformed fibroblasts, because the protein target of RSL3 is
not HRAS itself, but is a protein associated with the oncogenictd All rights reserved
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genic RAS signaling, regardless of subtype of RAS (H, N, or
KRAS) or tissue origin (sarcomas or carcinomas). To test this
hypothesis, we cultured Calu-1 cells, which were derived from
a human lung carcinoma, and attenuated oncogenic RAS signal-
ing by using shRNAs targeting HRAS, NRAS, or KRAS. RSL3
became less effective in Calu-1 cells expressing shRNAs target-
ing each RAS isoform, regardless of subtype (Figure 6C). Treat-
ment with shRNAs targeting RAS isoforms did not lead to a gen-
eral survival effect, since we did not observe loss of sensitivity to
staurosporine (Figure S4).
Oncogenic RASSignaling Enriches theCellular Iron Pool
by Regulating Expression Levels of TfR1, FTH1, and FTL
It was of interest that all RSLs were inhibited by an iron chelator,
DFOM. We decided to test an additional iron chelator, com-
pound 311 (Green et al., 2001), to test whether the protective
effect of DFOM comes from its ability to deplete iron, or from
other factors that may be specific to DFOM. We were able to
confirm depletion of the cellular iron pool by both iron chelators
with the fluorescent iron sensor, Phen Green SK (PGSK) (data
not shown). This cell-permeable dye has green autofluores-
cence, which diminishes upon binding to cellular iron (Petrat
et al., 2000). Thus, we saw increased fluorescence intensity in
iron-chelator-treated BJ-TERT/LT/ST/RASV12 cells. When we
treated these cells with RSLs in the presence of these iron che-
lators, the activities of the RSLs were significantly inhibited,
highlighting the importance of iron levels for inducing lethality
(Figure 7A).
We reasoned that these engineered tumor cells might have in-
creased iron content compared to their nontumorigenic counter-
parts, causing us to identify iron-dependent lethal compounds in
this screen for synthetic lethality. To test this hypothesis, we ex-
amined cellular iron levels by using PGSK (Figure 7B). When we
detected the intensity of fluorescence from PGSK-treated BJ
cells by flow cytometry, we found that BJ-TERT and BJ-TERT/
LT/ST cells showed a similar profile, whereas BJ-TERT/LT/ST/
RASV12 cells showed decreased fluorescence (Figure 7B). This
indicates that BJ-TERT/LT/ST/RASV12 cells have a greater basal
level of iron than their isogenic precursors.
We suspected that iron-metabolism-related proteins in BJ-
TERT/LT/ST/RASV12 cells might be altered to allow increased
iron uptake and maintenance in response to introduction of on-
cogenic RAS. Transferrin receptor 1 (TfR1) is a membrane pro-
tein that binds to the transferrin-iron complex and is internalized
to release iron within the cytoplasm (Cheng et al., 2004). We
monitored the expression level of TfR1 by western blot and
detected an increase in BJ-TERT/LT/ST/RASV12 (Figure 7C).
Thus, one explanation as to how BJ-TERT/LT/ST/RASV12 cells
exhibit greater levels of iron is that they have more TfR1, which
leads to increased iron uptake.
We wanted to validate the importance of iron in RSL-induced
cell death by reducing iron levels by a genetic method and then
comparing drug sensitivity between the modified cell line and the
parental cell line. Three different shRNAs targeting TfR1 were
delivered to BJ-TERT/LT/ST/RASV12 cells by a lentiviral system
(Moffat et al., 2006). Two shRNA clones displayed moderate
level of knock down efficiency (clone 658 and 659), whereas
one shRNA clone was not effective, as assessed by westernChemistry & Biology 1blot analysis (clone 660) (Figure 7D). When we tested erastin in
these cells, erastin became less effective in clone-658-express-
ing and clone-659-expressing cells, compared to clone-660-ex-
pressing and nontargeting-shRNA-expressing cells (Figure 7E).
However, the level of cell death suppression was not compara-
ble to that of iron-chelator-treated cells (compare Figures 7A
and 7E). This partial rescuing activity of shRNAs targeting TfR1
may reflect insufficient level of knock down or the existence of
other mechanisms for enriching the iron content of RAS-trans-
formed cells.
To explore other aspects of oncogenic-RAS signaling relevant
to iron enrichment, we compared the expression level of other
genes whose functions are known to modulate cellular iron con-
tent. The TfR1-mediated pathway is one route of iron uptake, but
the cellular iron pool is also controlled by an iron storage protein
complex, consisting of ferritin heavy chain 1 (FTH1) and ferritin
light chain (FTL) (Harrison and Arosio, 1996). Real-time RT-
PCR analysis showed a gradual increase in TfR1 mRNA levels
across the BJ-TERT, BJ-TERT/LT/ST, and BJ-TERT/LT/ST/
RASV12 cells, in agreement with western blot analysis (Figures
7F and 7C). Interestingly, the expression level of both FTH1
and FTL was specifically decreased in BJ-TERT/LT/ST/RASV12
cells (Figure 7F), indicating that oncogenic-RAS-signaling has
a dual-prong mechanism to augment the cellular labile iron
pool: one is to increase iron uptake via upregulation of TfR1,
the other is to reduce the capacity of iron storage via downregu-
lation of FTH1 and FTL.
DISCUSSION
In this synthetic lethal screening system, we used oncogenic
RAS (HRASG12V, although all hits were tested for oncogenic-
KRAS-selectivity); we searched for compounds with increased
lethality in the presence of this mutation. It is possible that
some hits from such a screen might have selectivity toward
HRAS, but not other RAS isoforms; such small molecules are
potentially useful research tools to define differences in down-
stream signaling pathways activated by different RAS isoforms.
Even in this case, it is important to note that the target protein
for the compound would be very unlikely to be HRASG12V itself.
According to the concept of synthetic lethality, one mutation is
HRASG12V, and the hit compound simulates a second mutation
in gene B by binding to protein B (Figure 1A).
This implies that a synthetic lethal screening strategy enables
us to target the oncogenic-RAS-signaling pathway, without
inhibiting RAS proteins themselves, which provides a broader
range of targets in a single screen compared to conventional
target-based in vitro screening. For example, these novel com-
pounds (RSL5 and RSL3) display RAS-RAF-MEK-signal-depen-
dent activity. As all three RAS isoforms can activate downstream
RAF-MEK signaling cascades, the synthetic lethality of RSL5
and RSL3 is not limited to HRASG12V. We demonstrated this
isoform-independent action of RSL3 by using shRNAs targeting
the three RAS genes in a lung-carcinoma-derived cell line (Fig-
ure 6C). It should be noted that due to the remoteness of the tar-
get protein from RAS, other oncogenes may also sensitize cells
to these RSL compounds if they activate signaling pathways
largely overlapping with RAS.5, 234–245, March 2008 ª2008 Elsevier Ltd All rights reserved 239
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Oncogenic-RAS-Signaling-Dependent Lethal CompoundsFigure 5. RSL3 Induces Rapid and Nonapoptotic Cell Death in Oncogenic RAS Containing Tumorigenic Cells
(A) Kinetic analysis of cell death induced by erastin, RSL5, and RSL3. RSL3 induced growth inhibition as early as 8 hr after drug treatment. Cells were seeded in
6-well plates in the presence of 5 mg/ml of erastin, 20 mg/ml of RSL5, or 0.5 mg/ml of RSL3. Cell viability was determined by Trypan Blue exclusion after 4, 8, 11, 12,
and 13 hr of drug treatment. The graph is a representative outcome of twice experiments.240 Chemistry & Biology 15, 234–245, March 2008 ª2008 Elsevier Ltd All rights reserved
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Oncogenic-RAS-Signaling-Dependent Lethal CompoundsErastin and RSL5 exploit VDAC3 to induce synthetic lethality
with oncogenic RAS. VDACs (VDAC1, VDAC2, and VDAC3) are
mitochondrial pores that transport ions and small metabolites,
including NADH, citrate, and succinate (Lemasters and Holmu-
hamedov, 2006). The use of VDACs as cancer-cell-selective
drug targets has not been addressed, except in our previous
report of erastin-induced, nonapoptotic, oxidative cell death.
The presence of a compound, RSL5, that uses VDACs to induce
selective lethality in oncogenic-RAS-containing cancer cells
emphasizes the importance of VDACs as novel targets with a
(B) Time-dependent effect of RSL3 on BJ-TERT, BJ-TERT/LT/ST, and BJ-TERT/LT/ST/RASV12 cells. Cells were seeded in 6-well plates in the presence of the
increasing concentration of RSL3. After 24, 48, and 72 hr, the number of viable cells was determined by using a Vi-Cell, and percent growth inhibition was
calculated. Bar graph is a representative outcome of multiple independent experiments.
(C) Photograph of BJ-TERT and BJ-TERT/LT/ST/RASV12 cells treated with 5mg/ml of erastin, 20mg/ml of RSL5, 0.5mg/ml of RSL3, or 1mM of staurosporine for 24 hr.
(D) Staurosporine-treated but not erastin-treated, RSL5-treated, or RSL3-treated BJ-TERT/LT/ST/RASV12 cells contain the PARP-1 fragment produced by cas-
pase-3/7 cleavage. Lysates of each treated samples were prepared. Ten micrograms of each lysate was analyzed by western blot with an antibody directed against
human PARP-1.
Figure 6. The Selective Lethality of RSL3 Is
Not Confined to Mutant HRAS-Containing
Cancer Cell Lines
(A) RSL3 was active in killing four KRAS mutation
harboring cancer cells. A549, Calu-1, PaCa-2,
and HCT116 cells were treated with RSL3 in
384-well plates for 24 hr. Percent growth inhibition
was calculated with alamar blue. Error bars indi-
cate one standard deviation of triplicate data.
(B) The activity of RSL3 was tested in 60 different
human cancer cell lines. The left chart shows the
result of 18 cell lines consisting of representative
sensitive and resistant groups. Zero viability indi-
cates a cytostatic effect of a compound, whereas
negative viability indicates a cytotoxic effect. The
right table shows results of the COMPARE analy-
sis for paclitaxel and RSL3. The sensitivity profile
of paclitaxel across 60 cancer cell lines has
a strong correlation with those of other microtu-
bule modulating agents. However, the top scored
PCC value for RSL3 was 0.503, suggesting that
RSL3 has a distinct sensitivity profile compared
to other anticancer agents.
(C) Attenuating RAS signaling in Calu-1 cells by in-
fecting with lentivirus containing shRNAs target-
ing H, N, or KRAS confers resistance to RSL3-in-
duced lethality. Virus-infected cells were seeded
in 384-well plates and treated with RSL3 for 24 hr.
Percent growth inhibition was determined with
alamar blue. Error bars indicate one standard
deviation of triplicate data.
sufficient degree of promiscuity in their
interaction with small-molecule ligands
to enable multiple scaffolds to target
these proteins.
One interesting shared property of
RSLs is their iron-dependent mechanism
of action. Many cancer cells are reported
to have an enriched iron pool (Shterman
et al., 1991); cancer patients have higher
levels of iron than normal individuals
(Stevens et al., 1988). Our BJ cell system
captured this relationship between iron and cancer as BJ-TERT/
LT/ST/RASV12 cells have more iron than their isogenic, nontu-
morigenic counterparts (Figure 7B). The greater iron content in
BJ-TERT/LT/ST/RASV12 cells, together with the iron-dependent
action of RSLs, lead us to the idea that the increased iron pool
within cancer cells might be a target for inducing cancer-cell-
specific lethality. Indeed, investigators have explored this possi-
bility by testing iron chelators for anticancer properties (Kalinow-
ski and Richardson, 2005). A number of iron chelators are
reported to have good potency in inhibiting cancer cell growth.Chemistry & Biology 15, 234–245, March 2008 ª2008 Elsevier Ltd All rights reserved 241
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Oncogenic-RAS-Signaling-Dependent Lethal CompoundsFigure 7. Oncogenic RAS Signaling Increases the Cellular Iron Content by Modulating Expression of TfR1, FTH, and FTL
(A) Iron chelators with different structures were able to suppress erastin-induced, RSL5-induced, and RSL3-induced cell death. BJ-TERT/LT/ST/RASV12 cells
were treated with erastin (left), RSL5 (center), or RSL3 (right) in the presence or absence of iron chelators. Value represents the mean ± SD of triplicate data.
(B) BJ-TERT/LT/ST/RASV12 cells have a greater basal iron pool than their isogenic counterparts. BJ-TERT, BJ-TERT/LT/ST, BJ-TERT/LT/ST/RASV12 cells were
stained with PGSK, and the fluorescence profile of stained cells was analyzed by flow cytometry.242 Chemistry & Biology 15, 234–245, March 2008 ª2008 Elsevier Ltd All rights reserved
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Oncogenic-RAS-Signaling-Dependent Lethal CompoundsFor example, bleomycin, a key component of standard chemo-
therapeutic regimens for treating patient with germ-cell tumors
(Kondagunta and Motzer, 2006), is known to oxidatively damage
DNA through its complex with iron (Dorr, 1992). Another iron che-
lator, Triapine, entered phase II clinical trials in a combination
therapy with cisplatin to treat ovarian cancer (Low and Schoen-
feldt, 2005).
The increased iron concentration in BJ-TERT/LT/ST/RASV12
cells compared to their isogenic counterparts raised the possibility
that oncogenic-RAS signaling alters iron metabolism to augment
the cellular labile iron pool (Figure 7B). Oncogene-induced in-
creases incellular ironhavebeenreported for c-myc andE1A (Tsuji
et al., 1995; Wu et al., 1999). Oncogenic signals from c-myc or E1A
downregulate expression of the heavy subunit of ferritin (FTH1),
which is a subunit of iron storage complex. Since ferritin functions
as an iron buffer, downregulation of ferritin by oncogenic signals
may result in an increased labile intracellular iron pool. Conse-
quently, proliferation-driving enzymes, such as ribonucleotide
reductase, are replenished with sufficient iron to function.
Oncogenic RAS has been proposed to enrich the cellular iron
pool mainly by upregulation of TfR1 expression. The existence of
a mitogen-responsive element in the 50 untranslated region (UTR)
of TfR1 mRNA has been reported, indicating that RAS-RAF-
MEK-MAPK signaling may upregulate TfR1 (Casey et al., 1988;
Ouyang et al., 1993). Our data are consistent with this hypothe-
sis; BJ-TERT/LT/ST/RASV12 cells have increased mRNA and
protein levels of TfR1 compared to BJ-TERT and BJ-TERT/LT/
ST cells (Figures 7C and 7F). In addition to this TfR1-mediated
pathway, we found that oncogenic RAS downregulates FTH1
and FTL to decrease the capacity of ferritin iron storage
(Figure 7F). As c-myc and E1A were reported to downregulate
FTH1 expression, it would be interesting to test whether ferritin
downregulation is a common means to enrich the cellular iron
pool by oncogenes. Moreover, efforts to identify target proteins
of RSL3 may ultimately reveal novel proteins in iron metabolism
regulation; some such proteins are likely to be connected to RAS
signaling.
These data demonstrate that synthetic lethal screening makes
it possible to identify small molecules with enhanced lethality
toward oncogene-harboring cancer cells, without targeting the
oncogene itself. This feature of synthetic lethal screening
becomes useful when we seek drug leads targeting loss of func-
tion cancer mutations, such as RAS, or tumor suppressors.
Mechanism of action studies with these small molecules may
lead to discovery of novel pharmacological targets for treating
cancer and elucidation of critical connections between the tar-
gets and the cancer genes of interest; this should allow for a re-
fined diagram of signaling networks in tumor cells.Chemistry & Biology 1SIGNIFICANCE
Synthetic lethal screening using small molecules involves
testing compounds for selective lethality in tumor cells har-
boring a specific oncogenic mutation. While small mole-
cules identified from target-based, in vitro screening directly
inhibit function of a fixed target, small molecules identified
from synthetic lethal screening do not perturb the function
of the mutated gene; they ‘‘synthesize’’ lethality by targeting
a protein component within the signaling network of the
mutated gene. Therefore, small molecules identified from
synthetic lethal screens are useful in identifying novel com-
ponents of signaling networks of interest. We used onco-
genic RAS (HRASG12V) as a specific mutation in synthetic
lethal screening and identified two compounds, RSL5 and
RSL3, whose activity depends on oncogenic RAS signaling.
In order to define the mechanism of action for these com-
pounds, we carried out counter screening with biologically
active compounds to find suppressors of cell death induced
by RSL5, RSL3, and erastin, a previously identified onco-
genic-RAS-signal-dependent lethal compound. The efforts
resulted in the identification of MEK, iron, reactive oxygen
species, protein synthesis, and other kinases as selectiv-
ity-determining factors for each compound. Comparison of
selectivity-determining factors among these compounds
allowed us to reveal that RSL5, like erastin, acts through
VDAC3 and provided some mechanistic insight into the ac-
tion of RSL3. The counter screening also revealed that cellu-
lar iron is an important factor in inducing synthetic lethality
with oncogenic RAS. Further analysis revealed that onco-
genic RAS upregulates TfR1 and downregulates FTH1 and
FTL to increase the labile iron pool. In conclusion, we identi-
fied two compounds from synthetic lethal screening involv-
ing oncogenic RAS, presented a means of using biologically
active compounds to study the mechanisms of these com-
pounds’ action, and used these oncogenic-RAS-signal-
dependent compounds to understand how oncogenic RAS
enriches the cellular iron pool, which is an important factor
for enabling oncogenic-RAS-selective lethality.
EXPERIMENTAL PROCEDURES
Please see the Supplemental Experimental Procedures for detailed descrip-
tions of screening procedures and lentivirus production.
Cell Lines
BJ-fibroblast-derived cell lines were grown in a 4:1 mixture of DMEM to M199
supplemented with 15% heat-inactivated fetal bovine serum. The human
fibrosarcoma cell line HT1080 was maintained in DMEM supplemented with(C) BJ-TERT/LT/ST/RASV12 cells have more TfR1 protein than that in their isogenic counterparts. Lysates of BJ-TERT, BJ-TERT/LT/ST, and BJ-TERT/LT/ST/
RASV12 cells were analyzed by western blot with an antibody directed against TfR1. We included an antibody directed against actin for assessing protein loading
amount.
(D–E) Knocking down TfR1 in BJ-TERT/LT/ST/RASV12 cells partially inhibits cell death induced by erastin. Whole-cell lysates from BJ-TERT/LT/ST/RASV12 cells
infected with either nontargeting shRNA (N.T.) or three different TfR1-targeting shRNAs (658, 659, 660) were prepared, and the level of TfR1 in each cell line was
determined by western blot with an antibody against TfR1 (D). The same set of cell lines was treated with indicated concentration of erastin and percent growth
inhibition was determined with alamar blue (E). Error bars indicate one standard deviation of triplicate data.
(F) Oncogenic RAS upregulates TfR1 but downregulates FTH1 and FTL. Cellular RNAs were prepared from each cell line, and real-time PCR was performed
with each gene-specific primer set. The expression levels of TfR1, FTH1, and FTL were first normalized to the level of endogenous control (RPLPO). The rel-
ative expression level of each gene among the three cell lines was expressed as a ratio of transcripts in a cell line to those in BJ-TERT. Value represents the
mean ± SD of three measurements of each sample.5, 234–245, March 2008 ª2008 Elsevier Ltd All rights reserved 243
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Oncogenic-RAS-Signaling-Dependent Lethal Compoundsnonessential amino acids and 10% calf serum. The human lung carcinoma cell
line Calu-1 and colon carcinoma cell line HCT116 were grown in McCoy’s 5A
medium supplemented with 10% calf serum. A human lung carcinoma cell line
A549 was grown in DMEM supplemented with 10% calf serum. The human
pancreatic carcinoma cell line MIA PaCa-2 was maintained in DMEM sup-
plemented with 10% calf serum and 2.5% horse serum. Penicillin and strepto-
mycin were used as antibiotics in all media.
Compound Libraries
Chemical libraries were composed of a combination of synthetic and natural
product-like compounds. In total, 47,725 small molecules were obtained
from different providers; 2,056 from TimTec, 8,669 from IBS, 17,520 from
Chembridge, 12,240 from Asinex, 5,240 from Life chemicals, and 2,000 from
MicroSource Discovery. All compounds were prepared as 4 mg/ml solutions
in DMSO in 384-well polypropylene plates (Greiner, cat. #781280) and stored
at 80C. We refer to these plates as mother plates.
Viability Assay
Alamar Blue Assay
After 24 or 48 hr of compound treatment, 10 ml of 50% alamar blue solution in
growth medium was transferred to the assay plates, which resulted in 10% fi-
nal concentration alamar blue. Plates were incubated further for 16 hr to allow
reduction of alamar blue, which results in the generation of red fluorescence.
The fluorescence intensity was determined by using a Victor 3 plate reader
(Perkin Elmer) with a 535 nm excitation filter and a 590 nm emission filter.
Trypan Blue Assay
200,000 cells were seeded in 6-well plates and treated with indicated amount
of 2-fold dilution series concentration of compound in 2 ml BJ growth medium.
After 24 hr, cells were released with trypsin/EDTA, harvested in 1.1 ml growth
medium, and transferred to Vi-Cell (Beckman Coulter) disposable cup. Trypan
blue staining, taking 100 images of sample and analysis of the images were
carried out automatically by the Vi-Cell.
Counter Screening with Iron Chelators
BJ-TERT/LT/ST/RASV12 cells were seeded in 384-well assay plates at a con-
centration of 4,000 cells per well in 32 ml volume. Cells were treated with iron
chelators by transferring 4 ml of 1 mM deferoxamine mesylate (Calbiochem,
cat. #252750), or 125 mM compound 311 (Chembridge, cat. #5135701) in
growth media to the assay plate. Then, we transferred 4 ml from the ‘‘103 lethal
plate’’ (described in Counter Screening with Biologically Active Compounds in
the Supplemental Experimental Procedures) to the assay plate in order to in-
duce cell death. Assay plates were incubated for 24 hr, and alamar blue was
added to the plates at a final concentration of 10%.
Monitoring Cellular Iron Level Using Flow Cytometry
Cells were seeded in 6-well plates (200,000 cells per well) in BJ medium. The
next day, the cell monolayer was washed with PBS twice and stained with
5 mM of Phen Green SK, diacetate (Molecular Probe, cat. #P14313) in PBS
by incubating the plate for 15 min in culture incubator. Cells were released
with trypsin/EDTA, harvested in 2 ml PBS, and centrifuged at 1,000 rpm for
5 min. The cell pellet was resuspended in 1 ml of PBS, the cell suspension
was transferred to disposable FACS tubes, and fluorescence profile of the
sample was monitored by using a FACSCalibur system (BD Biosciences).
Western Blot
Monitoring Cleavage of PARP1 and Caspase-3 upon Compound
Treatment
2 3 106 BJ-TERT/LT/ST/RASV12 cells were seeded in 10 cm dishes and
treated with 1 mM staurosporine, 10 mg/ml erastin, 20 mg/ml RSL5, and 1 mg/ml
RSL3 for 16 hr. Both dying cells and live cells in each 10 cm dish were har-
vested and collected in the same 15 ml tubes by centrifuging cell suspension
at 1,000 rpm for 5 min. Cell pellets were washed three times with PBS, and
cells were lysed in 200 ml of denaturing lysis buffer (50 mM HEPES KOH [pH
7.4], 40 mM NaCl, 2 mM EDTA, 1.5 mM Na3VO4, 50 mM NaF, 10 mM sodium
pyrophosphate, 10 mM sodium b-glycerophosphate, 0.5% Triton X-100, and
protease inhibitor tablet [Roche, cat. #11836170001]). Protein content was
quantified by using a Bio-Rad protein assay reagent (Bio-Rad, cat. #500-
00006). Equal amounts of protein were resolved on SDS-polyacrylamide244 Chemistry & Biology 15, 234–245, March 2008 ª2008 Elsevier Lgels. The electrophoresed proteins were transblotted onto a PVDF membrane,
blocked with 5% milk, and incubated with rabbit primary antibodies specific
to: PARP (Santa Cruz, cat. #sc-7150), cleaved caspase-3 (Cell Signaling Tech-
nology, cat. #9661) overnight at 4C. The membrane was then incubated in
IRDye 800 goat anti-rabbit antibody (Li-Cor Bioscience cat. #926-32211) at
1:3,000 dilutions for 45 min at room temperature. After washing off the
unbound antibodies, membranes were scanned with the Odyssey Imaging
System (Li-Cor Bioscience).
Basal Expression Level of TfR1
BJ-TERT, BJ-TERT/LT/ST, and BJ-TERT/LT/ST/RASV12 cells were seeded
prior to the experiment in 10 cm dishes and allowed to grow to 80% conflu-
ence. The cell monolayer was washed three times with PBS, and cells were
lysed in 200 ml of denaturing lysis buffer. The cell lysates were subjected to
western blot analysis as described above. An antibody directed against human
transferrin receptor 1 (Santa Cruz, cat. #sc-7087) was used.
Monitoring Drug Sensitivity in shRNA-Expressing Cells
HT1080 or Calu-1 cells were infected with lentiviruses that contain shRNA ex-
pression plasmids as described in the Supplemental Experimental Proce-
dures. On the day of experiment, assay plates were prepared by seeding
1,500 shRNA-infected cells per well in 36 ml of growth media to black, clear-
bottom 384-well plates. Cells in the assay plates were treated with each lethal
compound in a 2-fold dilution series by transferring 4 ml solution from a 103
lethal plate of erastin, RSL5, RSL3, or staurosporine. Assay plates were re-
turned to the culture incubator and maintained for 24 hr before adding alamar
blue. Percent growth inhibition (% GI) was calculated with fluorescence inten-
sity values.
Real-Time RT-PCR
Total RNA was extracted with RNeasy kit (QIAGEN, cat. #74104) as described
in the manufacturer’s handbook. One microgram of RNA sample was subject
to reverse transcription reaction by using TaqMan Reverse Transcription Re-
agents (Applied Biosystems, cat. #N8080234) according to the manufacturer’s
instruction. Then, Q-PCR was carried out by using Power SYBR Green PCR
Master Mix (Applied Biosystems, cat. #4367659) and 7300 Real-Time PCR
System (Applied Biosystems). The sequence of primers for Q-PCR is shown
in the Supplemental Data.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, four fig-
ures, one table, and sequence of primes used and can be found with this article
online at http://www.chembiol.com/cgi/content/full/15/3/234/DC1/.
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